sign in sign up
<<
Home , Adrenalone, Bendroflumethiazide, Benidipine, Conivaptan, Levobetaxolol, Methyclothiazide

IIN UN TORN UNTUKTA US IN20170304388A1 AN ATAU MANA NA ANTH ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017/ 0304388 A1 Chen et al. ( 43 ) Pub . Date: Oct. 26 , 2017

(54 ) NEW INDICATION OF CARDIOVASCULAR A61K 31/ 549 ( 2006 . 01 ) DRUGS FOR PREPARATION OF CANCER A61K 31 /505 (2006 .01 ) INHIBITION PHARMACEUTICAL A61K 31 / 404 ( 2006 .01 ) COMPOSITION A61K 31/ 366 ( 2006 .01 ) A61K 31 /341 ( 2006 . 01 ) (71 ) Applicant: LAUNX BIOMEDICAL CO ., LTD ., A61K 31 /216 ( 2006 .01 ) Kaohsiung ( TW ) A61K 31/ 197 (2006 .01 ) A61K 31/ 196 ( 2006 .01 ) ( 72 ) Inventors : Chiu -Hung Chen , Kaohsiung ( TW ) ; A61K 45 / 06 ( 2006 . 01 ) Show -Mei Chuang, Taichung ( TW ); A61K 31 / 138 ( 2006 . 01) Nai- Wan Hsiao , Taichung ( TW ) ; (52 ) U . S . CI. Ruei- Yue Liang , Taichung ( TW ) ; CPC ...... A61K 38 /05 (2013 . 01 ); A61K 45 / 06 Xiao - Tong Tan , Taichung ( TW ) ( 2013 .01 ) ; A61K 31 / 7056 ( 2013 .01 ) ; A61K 31/ 55 (2013 .01 ) ; A61K 31 /549 ( 2013 .01 ) ; (73 ) Assignee : LAUNX BIOMEDICAL CO ., LTD ., A61K 31 /505 ( 2013 . 01 ) ; A61K 31/ 138 Kaohsiung ( TW ) (2013 . 01 ) ; A61K 31/ 366 ( 2013 . 01 ); A61K 31/ 341 ( 2013 .01 ) ; A61K 31/ 216 ( 2013 .01 ) ; (21 ) Appl. No. : 15 /521 , 536 A61K 31 / 197 (2013 . 01 ); A61K 31/ 196 ( 22 ) PCT Filed : Oct. 23 , 2015 ( 2013. 01 ) ; A61K 31/ 404 ( 2013. 01 ) (57 ) ABSTRACT ( 86 ) PCT No. : PCT/ CN2015 /092768 A method for treating a cancer includes administering to a $ 371 (c )( 1 ), subject in need thereof a pharmaceutical composition con ( 2 ) Date : Apr. 24 , 2017 taining a therapeutically effective amount of a cardiovascu lar drug or a pharmaceutical acceptable salt thereof. The Related U .S . Application Data cardiovascular drug is selected from the group consisting of peripheral vasodilator reaming enhancer, angiotensin con (60 ) Provisional application No . 62/ 068 , 298 , filed on Oct. verting agent inhibitor, hypotension and shock therapeutic 24 , 2014 . agent, , antiarrhythmic agent, antiarralciton drug , antihypertensive agent, anticoagulant thrombolytic agent, Publication Classification cardiac tonic , and intravenous (hemorrhoids ) therapeutic (51 ) Int. CI. agent . The cancer is selected from the group consisting of A61K 38 /05 ( 2006 . 01 ) lung cancer , intestinal cancer , colorectal cancer, prostate A61K 31/ 7056 ( 2006 .01 ) cancer, liver cancer , bladder cancer , cervical cancer, breast A61K 31/ 55 ( 2006 .01 ) cancer, and blood cancer. Patent Application Publication Oct 26 , 2017 US 2017 / 0304388 A1

-????? Huslepia? fantsDIDELIS poidang IslangeBullet DITHESLLAT ramper TajMaan VÝ IMAGEseudoshladi REFIFIABLE . agromexcursioniO danossie 2903 Neza. . . BuBadgetPudpudingMenstagorious anlataudeep Oksiaze guid ": tamentosKontaktpara FIG.1 TUIM actoRECES k :::: : :

asdiendesigurkapsasen desu ???? es N ??? ???. omiseoguden MESEDapis HarTRADIO Festivalipigannoha noeper OMDETTEupu za Dummmmmmmmmmmmmmmmmmmmmmmmmmmmmm Namopdan 1901 410Pqmurje Xapuj HORO US 2017 /0304388 A1 Oct. 26 , 2017

NEW INDICATION OF CARDIOVASCULAR patient selection , trial dose and other issues . Even the drug DRUGS FOR PREPARATION OF CANCER has approved by the FDA and sales on the market , there still INHIBITION PHARMACEUTICAL possibly face the situation of the poor drug response in COMPOSITION patients . Furthermore , if the cancer patients happen the drug resistance , that would reduce the effectiveness of the drugs CROSS -REFERENCE TO RELATED and result in the medical treatment failure . Therefore , the APPLICATIONS new drug development is very difficult. [0001 ] This is a National Phase Application filed under 35 U . S . C . 371 as a national stage of PCT/ CN2015 / 092768 filed SUMMARY OF THE INVENTION Oct. 23 , 2015 , an application claiming the benefit under 35 [0009 ] To solve the above problems, the present invention USC 119 ( e ) to the following U . S . Provisional Applications provides a usage of existing cardiovascular drugs , which No. 62 / 068, 298 filed Oct. 24 , 2014 , the content of each of have passed clinical trials . which is hereby incorporated by reference in its entirety. 10010 ] The experiment results showed that the cardiovas cular drugs had no toxicity or only little toxicity to normal FIELD OF THE INVENTION cells . However , there are more studies need to be test to [0002 ] The present invention provides new clinical indi know that whether the cardiovascular drugs have selection cation of cardiovascular drugs , which were approved by between normal cells and cancer cells . Besides , not all the FDA . Particularly , the present invention demonstrates that cardiovascular drugs could inhibit the growth of cancer cells the cardiovascular drugs can effectively inhibit a variety of under same condition , there are still lots of problemsneed to be overcame. cancers . [0011 ] Term Definition [0012 ] The cardiovascular drugs can be classified to ten BACKGROUND OF THE INVENTION categories based on the features , includes : peripheral vaso [0003 ] Cancer is the most popular disease cause of death dilator reaming enhancer, angiotensin converting agent in the world . The cancer patients are gradually increase inhibitor , hypotension and shock therapeutic agent, diuretic , yearly, therefore the treatment method of the cancer has antiarrhythmic agent, antiarralciton drug , antihypertensive become an important issue . The medical treatments of agent, anticoagulant and thrombolytic agent, cardiac tonic , cancer can be classified as surgical treatment, radiation intravenous (hemorrhoids ) therapeutic agent. therapy, chemotherapy and target therapy. [0013 ] ( 1 ) Peripheral vasodilator reaming enhancer, which [0004 ] Generally, the cancer drug , whether chemotherapy can directly or indirectly effect on peripheral blood vessels drug or target therapy drug , is inhibit the cancer cells ' to increase blood flow , includes: , , duplication and split to prevent the tumor growth and HCl, Sildenafil citrate , Tadalafil (Cialis ) , Nic metastasis . In clinical treatment options , the combination of orandil ( Ikorel ) , (Lacipil , Motens ) , Benidipine chemotherapies and several targeted therapies were selected ; hydrochloride , Cilazapril monohydrate ( Inhibace ) , Fosino try to eliminate cancer cells more effectively , by means of pril sodium (Monopril ) , Almotriptan malate (Axert ) , Milri different mechanisms. Furthermore , if the cancer patients none (Primacor ) , Avanafil , HC1, Histamine happen the drug resistance , that would reduce the effective Phosphate , Chromocarb and . ness of the drugs and result in the medical treatment failure . [0014 ] ( 2 ) Angiotensin converting agent inhibitor, which [0005 ] On the other side , treatment of cardiovascular is used to inhibit ACE activity and reduce the production of disease aims to prevent or delay the progression of the II, so as to reduce the bradykinin hydrolysis , disease . Also , it aims to reduce the risk of developing lead to vasodilatation , blood volume, and decrease blood cardiovascular diseases. For example , some cardiovascular pressure , includes: Benazepril hydrochloride , Losartan drugs can treat high blood pressure , and other cardiovascular potassium , Erbumine ( Aceon ), Irbesartan drugs can promote blood flow in patients with . (Avapro ) , Candesartan ( Atacand ) , Olmesartan medoxomil [0006 ] Based on the many years ' experience of inventors , (Benicar ) , Enalaprilat dehydrate , Telmisartan (Micardis ) , the human cancer cells and normal cells often have different Ramipril ( Altace ) , Valsartan (Diovan ) , Enalapril maleate characteristics, the differences in patterns or mechanism (Vasotec ) , Candesartan cilexetil ( Atacand ) , HC1 variation might be seen as a foreign invader. The different ( Vaprisol) , Azilsartan Medoxomil ( TAK -491 ) and Eprosar cancel cells are located in different locations and the statuses tan Mesylate . of variations are related to the located environment. Thus, [0015 ) ( 3 ) Hypotension and shock therapeutic agent, the inventors are the first person to propose the use of which includes : L - ( Epinephrine ) , DL - Adrena antibiotic drugs to inhibit the cancer cell growth . line and HCl. [0007 ] In contrast , these cardiovascular drugs have been [0016 ) ( 4 ) Diuretic , which is used to increase the genera used for decades and are recognized by FDA long time ago . tion of urine and increase the excretion of human body These cardiovascular drugs already have been researched water, includes : , ( Lasix ), Metola and analyzed to know the mechanism on human body. zone ( Zaroxolyn ), (Rapafio ) , , Therefore, the groundbreaking new application would be ( Achletin ) , Torsemide (Demadex ) , time- saving and cost effective if these drugs applied in , (Lozol ) , Dichlorphena treating cancer. Besides , the treatment effect would be mide ( ) , hydrochloride dehydrate , improved if these drugs are used to combine with other succinate , , Benzthiazide , treating method . , and . [0008 ] Otherwise , the manufacturing of the drug is also a [0017 ] ( 5 ) Antiarrhythmic agent, which is used to inhibit big problem . When the drug starting the clinical trials, there abnormal heartbeat rhythm (arrhythmia ) , such as atrial are lots of problems need to overcome, such as drug safety , fibrillation , atrial flutter , and ventricular tachycardia (ven US 2017 /0304388 A1 Oct. 26 , 2017 tricular tachycardia ) and ventricular fibrillation , includes : dihydrochloride, Sildenafil citrate , Perindopril Erbumine Adenosine ( Adenocard ) , ( Tikosyn ) , (Aceon ), Irbesartan (Avapro ) , Tadalafil (Cialis ), HC1, fumarate , (Rytmonorm ) and (Bystolic ) , Pimobendan (Vetmedin ) , Candesartan ( Atacand ) , Phosphate . Apixaban , Reserpine, Furosemide (Lasix ) , Olmesartan [ 0018 ] (6 ) Antiarralciton drug , which is used to treat medoxomil ( Benicar ), Pyridostigmine Bromide (Mestinon ), ischemic heart disease symptoms, includes Dexrazoxane ( Zaroxolyn ), Silodosin (Rapaflo ), Chlorothiaz Hydrochloride , dihydrochloride , ide , ( Aldomet ) , Adenosine (Adenocard ) , ( Sular ) , Ranolazine (Ranexa ) , Acadesine , ( Ada Ezetimibe ( Zetia ) , Enalaprilat dehydrate , Dofetilide ( Tiko lat ) , besylate (Norvasc ), HCl ( Ti syn ) , Trichlormethiazide ( Achletin ) , azac ), Ticagrelor and HCI ( Amicar ) , Busulfan (Myleran , Busulfex ) , Torsemide (Dema [ 0019] ( 7 ) Antihypertensive agent is a medicament for dex ) , , Hydrochlorothiazide, Gemfibrozil treatment, which is used to prevent high blood (Lopid ) , Indapamide (Lozol ) , Telmisartan (Micardis ), pressure complications, such as stroke and myocardial (Nimotop ) , Nisoldipine (Sular ), Pitavastatin infarction , includes: , mesylate , Alfu calcium (Livalo ), Simvastatin ( Zocor ) , Ramipril ( Altace ) , zosin hydrochloride (Uroxatral ) , Nebivolol (Bystolic ), Fenofibrate ( Tricor, Trilipix ), Ranolazine (Ranexa ), Reserpine, Methyldopa (Aldomet ) , Eplerenon , Nimodipine Acadesine , Acipimox , Nifedipine (Adalat ), Amlodipine (Nimotop ) , hydrochloride (Betoptic ) , , besylate (Norvasc ) , Clofibrate (Atromid - S ) , Betaxolol tartrate , (Plendil ) , Amlodipine (Nor hydrochloride (Betoptic ) , Carvedilol, Daidzein , toprolol tar vasc ) , mesilate , Imidapril ( Tanatril) HC1, trate , Diltiazem HC1 ( Tiazac ) , ( Transamin ) , Aliskiren hemifumarate , Sodium Nitroprusside, Felodipine (Plendil ), Valsartan ( Diovan ), Dipyridamole HC1, Levobetaxolol HC1, HCI, ( R ) - ( + ) - , ( Persantine ), Amlodipine (Norvasc ), Fluvastatin sodium and HC1. (Lescol ) , Phenindione (Rectadione ) , Enalapril maleate ( Va [ 00201 ( 8 ) Anticoagulant, thrombolytic agent is the flag sotec ), ( Ikorel) , Amiodarone HC1, Ticlopidine used to prevent blood ( coagulation ) . Those HC1, Lacidipine ( Lacipil , Motens ) , Suplatast tosylate , Beni substances exist in leeches and blood -sucking insects . Anti dipine hydrochloride , Ginkgolide A , Candesartan cilexetil coagulants can treat thrombotic diseases, include: Prasugrel ( Atacand ) , Phentolamine mesilate , , Cytidine , ( Effient ), Cilostazol, Nafamostat mesylate , Clopidogrel Bromhexine HCI, Tiopronin ( Thiola ) , Ozagrel HC1, Arga ( Plavix ) , Apixaban , Aminocaproic acid (Amicar ), Dipyrida troban , calcium , Rosiglitazone HC1, Atorvasta mole (Persantine ) , Phenindione (Rectadione ) , Ticlopidine tin calcium (Lipitor ), Famotidine (Pepcid ) , Cleviprex (Cle HC1, Ozagrel HC1, , Bexarotene , Gabexate mesy vidipine ) , Cilazapril monohydrate ( Inhibace ) , Adiphenine late and Ozagrel and Anisindione. HC1, Rivastigmine tartrate (Exelon ) , HCI, Fos [0021 ] (9 ) Cardiac tonic includes : Pimobendan (Vetme inopril sodium (Monopril ) , Almotriptan malate ( Axert ), din ) , , Digoxigenin and . Bexarotene , Gabexate mesylate , Rasagiline mesylate , Imi [0022 ] ( 10 ) Intravenous (hemorrhoids ) therapeutic agent dapril ( Tanatril ) HC1, Conivaptan HCl (Vaprisol ) , Ibutilide includes : Edaravone (MCI - 186 ) , Daidzein , Ginkgolide A fumarate , Probucol, Arbidol HCI, S - ( + ) - Rolipram , Tebi and Bisacodyl . penem pivoxil ( L -084 ), Dichlorphenamide (Diclofenamide ) , [0023 ] In one of the embodiments , the cancer is selected Aliskiren hemifumarate , DL - Carnitine hydrochloride , from lung cancer , intestinal cancer, colorectal cancer, pros D - (Osmitrol ) , L - carnitine ( Levocarnitine ), Aman tate cancer, liver cancer, bladder cancer, cervical cancer, tadine hydrochloride (Symmetrel ) , ( Clozaril ) , breast cancer and blood cancer . Milrinone (Primacor ), Mitoxantrone Hydrochloride , Novo [0024 ] In one of the embodiment of the present invention , biocin sodium (Albamycin ) , Ozagrel, Pancuronium (Pavu wherein the effect concentration of the drug in the present lon ) , Propafenone (Rytmonorm ) , Quinine hydrochloride invention is 20 mg /kg / day ~ 500 mg/ kg /day . dehydrate , Spectinomycin hydrochloride , HCI, L -Adrenaline (Epinephrine ), DL -Adrenaline , Trospium BRIEF DESCRIPTION OF THE DRAWINGS chloride (Sanctura ) , Amiloride hydrochloride dehydrate , Cloxacillin sodium (Cloxacap ) , Zidovudine (Retrovir ) , [ 0025 ] FIG . 1 illustrates the analysis of cardiovascular Thiamphenicol ( Thiophenicol) , Oseltamivir phosphate drugs for cancer cells inhibition . ( Tamiflu ) , , Peramivir Trihydrate , Carfilzomib DETAILED DESCRIPTION OF THE ( PR - 171) , Pazopanib , Fosaprepitant dimeglumine , Otilo INVENTION nium Bromide , Solifenacin succinate , Besifloxacin HC1 (Be sivance ) , Azilsartan Medoxomil ( TAK -491 ) , Creatinine , [0026 ] The present invention provides a usage of cardio Adrenalone HCI, Ampiroxicam , Desloratadine , Avanafil , vascular drugs for cancer inhibition pharmaceutical compo Bisacodyl, Methyclothiazide , Sodium Nitroprusside , Vita sition preparation , which feature is the pharmaceutical com min D3 ( Cholecalciferol) , Deferiprone, Propranolol HCI, position composed by an effective dosage of cardiovascular , Ticagrelor, sulfacetamide sodium , Lomer drug and a pharmaceutical acceptable salt . izine HC1, Levobetaxolol HCl, Dexlansoprazole , Esmolol [0027 ] The cardiovascular drug of the present invention HC1, Eprosartan Mesylate , Histamine Phosphate, Sevelamer includes : Lenalidomide Valproic acid sodium salt ( Sodium HC1, Deoxyarbutin , Clorprenaline HCL , Ethamsylate , Chro ), Decitabine , Bisoprolol, Dexrazoxane Hydro mocarb , Mevastatin , HC1, Phenazopyridine HC1, chloride, Prasugrel (Effient ) , Benazepril hydrochloride , ( R ) - ( + ) - Atenolol, Anisindione , Benzthiazide, Disopyramide Bumetanide, Cilnidipine , Cilostazol, Doxazosin mesylate , Phosphate , Guanethidine Sulfate , Isoetharine Mesylate , Edaravone (MCI - 186 ) , Losartan potassium , Minoxidil , Methoxamine HC1, Meticrane , Oxprenolol HCl, Pinacidil , Nafamostat mesylate , , hydrochloride Bendroflumethiazide , Potassium Canrenoate , Digoxigenin , (Uroxatral ) , Clopidogrel (Plavix ), Prazosin HC1, Ranolazine Lofexidine HCl and Pindolol . US 2017 /0304388 A1 Oct. 26 , 2017

[ 0028 ] Cell Culture TABLE 2 [0029 ] Subculture the different types of cancer cells . The The cardiovascular drugs which do not have cancer cells includes lung cancer , gastric cancer, hepatic significant inhibitory effect to cancer cells cancer, colon cancer, skin cancer, cervical cancer, prostate Numbers of inhibitory cancer, bladder cancer , breast cancer , leukemia , pancreatic cardiovascular drugs effect on cancer cell line cancer, ovarian cancer, tongue cancer, osteosarcoma, and Bisoprolol renal cancer. Cancer cell lines were cultured in different Benazepril hydrochloride culture medium according to different characteristics (as Bumetanide shown in Table 1 ) . The cell numbers were counted and Furosemide ( Lasix ) Trichlormethiazide ( Achletin ) rereseed as 2x10 in cell culture plate / flask . Then , the culture Aminocaproic acid ( Amicar ) medium for culturing the cell lines was added to a volume Indapamide (Lozol ) of 10 ml, and the cells were cultured for 2 - 3 days . Then , the Simvastatin (Zocor ) cells were suspended for loading into 96 -well plates. The Ramipril ( Altace ) Fenofibrate ( Tricor , Trilipix ) cell number was 3000 cells and the volume of the culture Acadesine medium was 100 ul each well . Acipimox Ticlopidine HCI Adiphenine HCI TABLE 1 Rivastigmine tartrate (Exelon ) Detomidine HCI Cancer cell lines and the culture medium Gabexate mesylate Rasagiline mesylate Culture S - ( + ) -Rolipram tumor Cell line medium Tebipenem pivoxil ( L -084 ) Lung cancer H1650 (Lung Adenocarcinoma ) RPMI Aliskiren hemifumarate A549 ( Lung Adenocarcinoma) DMEM Milrinone ( Primacor ) Stomach cancer AGS (Gastric Adenocarcinoma) RPMI Novobiocin sodium MKN - 45 (Gastric Adenocarcinoma) RPMI Ozagrel Liver cancer HepG2 (Hepatocellular Carcinoma) DMEM Pancuronium ( Pavulon ) Intestinal HCT116 ( Colorectal Carcinoma) DMEM Propafenone ( Rytmonorm ) cancer LoVo ( Colorectal Adenocarcinoma ) DMEM Xylazine HCl Skin cancer A375 ( Amelanotic Melanoma) DMEM L - Adrenaline (Epinephrine ) Cervical cancer Hela (Cervix Adenocarcinoma) DMEM Lonidamine Prºstate cancer PC3 (Prostate Adenocarcinoma) DMEM Bisacodyl Bladder cancer TSGH - 8301 (Urinary Bladder Carcinoma) RPMI Sodium Nitroprusside Breast cancer MCF7 (Mammary Gland , Adenocarcinoma) DMEM Mefenamic acid Leukemia HL - 60 ( Acute Promyelocytic Leukemia ) RPMI Ticagrelor sulfacetamide sodium Levobetaxolol HCI Dexlansoprazole [0030 ] Cell Viability Analysis Chromocarb Guanethidine Sulfate [0031 ] Removing the original culture medium from Isoetharine Mesylate 96 -well plate . Then add 100 ul of commercially drug at a concentration of 10 uM per well . After 72 hours, add the diluted WST - 1 reagent to the well with 100 ul/ well , and the [ 0035 ] Besides , the inhibition effects of different cardio diluted WST- 1 reagent was acquired from the dilution of 9 : 1 vascular drugs on different cancer cells were different medium and WST- 1 stock reagent . Finally , the total volume ( shown as FIG . 1 ) . According to the experiment, the of each well are 200 ul/ well . Culture the 96 -well plate at 37° Lenalidomide, Valproic acid sodium salt ooooooooooooooooooooooooooooooooooooooo( Sodium val proate ), Decitabine , Bisoprolol, Dexrazoxane Hydrochlo C . for 30 to 90 minutes . Detecting and calculating the ride, Prasugrel (Effient ) , Benazepril hydrochloride , survival rate of each cancer cells with an ELISA reader at Bumetanide , Cilnidipine , Cilostazol, Doxazosin mesylate , OD450 nm . The lower viability of cancer cells represents Edaravone (MCI - 186 ) , Losartan potassium , Minoxidil , better inhibition effect via the drugs . Otherwise , the higher Nafamostat mesylate , Bimatoprost , Alfuzosin hydrochloride viability of cancer cells represents worse inhibition effect via (Uroxatral ) , Clopidogrel ( Plavix ) , Prazosin HC1, Ranolazine the drugs . dihydrochloride , Sildenafil citrate , Perindopril Erbumine [0032 ] Growth Inhibitory Effects on Cancer Cell Lines by ( Aceon ), Irbesartan ( Avapro ), Tadalafil (Cialis ), Nebivolol Various Cardiovascular Drugs in the Present Invention (Bystolic ), Pimobendan ( Vetmedin ) , Candesartan ( Atacand ) , Apixaban , Reserpine , Furosemide (Lasix ), Olmesartan [0033 ] For cell viability analysis , the cardiovascular drugs medoxomil (Benicar ) , Pyridostigmine Bromide (Mestinon ) , include peripheral vasodilator reaming enhancer , angio Metolazone (Zaroxolyn ) , Silodosin (Rapaflo ), Chlorothiaz tensin converting agent inhibitor , hypotension and shock ide , Methyldopa ( Aldomet) , Adenosine (Adenocard ) , therapeutic agent, diuretic , antiarrhythmic agent, antiarral Ezetimibe (Zetia ), Enalaprilat dehydrate , Dofetilide ( Tiko citon drug , antihypertensive agent, anticoagulant throm syn ), Trichlormethiazide (Achletin ), Aminocaproic acid bolytic agent, cardiac tonic , intravenous (hemorrhoids ) ( Amicar ) , Busulfan (Myleran , Busulfex ) , Torsemide (Dema therapeutic agent , are used to test the inhibition effect of dex ) , Eplerenone , Hydrochlorothiazide, Gemfibrozil cancer cell. (Lopid ) , Indapamide (Lozol ) , Telmisartan (Micardis ), 0034 ] The test result showed that lots of cardiovascular Nimodipine (Nimotop ), Nisoldipine (Sular ) , Pitavastatin drugs had no effect on cancer cell lines growth inhibition calcium (Livalo ) , Simvastatin (Zocor ), Ramipril ( Altace ) , ( Table 2 ) . Fenofibrate (Tricor , Trilipix ), Ranolazine (Ranexa ), US 2017 /0304388 A1 Oct. 26 , 2017

Acadesine, Acipimox , Nifedipine ( Adalat ), Amlodipine L - Adrenaline ( Epinephrine ), DL - Adrenaline , Trospium besylate (Norvasc ) , Clofibrate (Atromid - S ) , Betaxolol chloride (Sanctura ) , Amiloride hydrochloride dihydrate , Cloxacillin sodium (Cloxacap ) , Zidovudine (Retrovir ) , hydrochloride (Betoptic ) , Carvedilol, Daidzein , toprolol tar Thiamphenicol ( Thiophenicol) , Oseltamivir phosphate trate , Diltiazem HC1 ( Tiazac ) , Tranexamic acid ( Transamin ) , ( Tamiflu ) , Lonidamine , Peramivir Trihydrate , Carfilzomib Felodipine ( Plendil ), Valsartan (Diovan ), Dipyridamole ( PR - 171) , Pazopanib , Fosaprepitant dimeglumine , Otilo (Persantine ) , Amlodipine (Norvasc ) , Fluvastatin sodium nium Bromide, Solifenacin succinate , Besifloxacin HC1 (Be (Lescol ) , Phenindione (Rectadione ) , Enalapril maleate ( Va sivance ), Azilsartan Medoxomil ( TAK - 491) , Creatinine, sotec ) , Nicorandil ( Ikorel) , Amiodarone HC1, Ticlopidine Adrenalone HC1, Ampiroxicam , Desloratadine , Avanafil , HC1, Lacidipine (Lacipil , Motens ) , Suplatast tosylate, Beni Bisacodyl, Methyclothiazide , Sodium Nitroprusside , Vita dipine hydrochloride , Ginkgolide A , Candesartan cilexetil min D3 (Cholecalciferol ) , Deferiprone , Propranolol HCl, ( Atacand ) , Phentolamine mesilate , Nimesulide , Cytidine , Mefenamic acid , Ticagrelor, sulfacetamide sodium , Lomer Bromhexine HC1, Tiopronin ( Thiola ) , Ozagrel HC1, Arga izine HC1, Levobetaxolol HCI, Dexlansoprazole , Esmolol troban , Mitiglinide calcium , Rosiglitazone HCl, Atorvasta HC1, Eprosartan Mesylate , Histamine Phosphate , Sevelamer tin calcium (Lipitor ) , Famotidine (Pepcid ) , Cleviprex (Cle HC1, Deoxyarbutin , Clorprenaline HCL , Ethamsylate , Chro vidipine ) , Cilazapril monohydrate ( Inhibace ). Adiphenine mocarb , Mevastatin , Mexiletine HC1, Phenazopyridine HCI, HC1, Rivastigmine tartrate ( Exelon ) , Detomidine HC1, Fos - (R )- ( + ) - Atenolol, Anisindione , Benzthiazide , Disopyramide inopril sodium (Monopril ), Almotriptan malate (Axert ), Phosphate , Guanethidine Sulfate , Isoetharine Mesylate , Bexarotene , Gabexate mesylate, Rasagiline mesylate , Imi Methoxamine HCI, Meticrane, Oxprenolol HCI, Pinacidil, dapril ( Tanatril) HCl, Conivaptan HCl ( Vaprisol) , Ibutilide Bendroflumethiazide , Potassium Canrenoate , Digoxigenin , fumarate , Probucol, Arbidol HC1, S - ( + ) - Rolipram , Tebi Lofexidine HCl and Pindolol showed significant inhibition penem pivoxil ( L - 084 ) , Dichlorphenamide (Diclofenamide ) , effect on different cancer cell lines (shown as Table 3 ) . Aliskiren hemifumarate , DL - Carnitine hydrochloride, [0036 ] Although the present invention has been described D -Mannitol (Osmitrol ) , L -carnitine (Levocarnitine ) , Aman in terms of specific exemplary embodiments and examples , tadine hydrochloride (Symmetrel ) , Clozapine ( Clozaril ) , it will be appreciated that the embodiments disclosed herein Milrinone (Primacor ), Mitoxantrone Hydrochloride , Novo are for illustrative purposes only , and various modifications biocin sodium (Albamycin ) , Ozagrel , Pancuronium (Pavu - might be made by those skilled in the art without departing lon ), Propafenone (Rytmonorm ), Quinine hydrochloride from the spirit and scope of the invention as set forth in the dihydrate , Spectinomycin hydrochloride , Xylazine HCl, following claims. TABLE 3 The inhibitory effect of cardiovascular drugs on various cancer cell lines Item Name A375 HCT116 (WT ) HepG2 HeLa AGS H1650 MKN - 45 TSGH A549 MCF7 PC3 LOVO HL - 60 Bisoprolol 117 . 4 118 . 0 107 . 5 110 . 8 80 . 3 79 . 7 87 . 5 123. 9 111. 9 95 . 2 118 . 8 85 . 7 Benazepril 104 . 0 60 . 0 93 . 0 75 . 9 76 . 7 61. 6 103. 3 77 . 5 81 . 8 126 . 1 80 . 7 96 . 0 93. 6 hydrochloride Bumetanide 67. 6 66 . 8 86 . 0 79 . 5 69. 9 105 . 2 98 . 8 92 . 6 88 . 2 116 . 3 72. 7 98. 6 98 . 3 Furosemide ( Lasix ) 87 . 6 92 . 6 103 . 5 98 . 2 97 . 4 80 . 6 64 . 2 76 . 5 142 . 0 104 . 8 191 . 9 112 . 2 100 . 3 Trichlormethiazide 128 . 4 111 . 5 95 . 1 85 . 7 79 . 3 76 . 7 71 . 0 95 . 6 106 . 3 64 . 2 122. 3 107 . 3 102 . 2 (Achletin ) Aminocaproic acid 122 . 7 114 . 2 101. 2 90 .4 64. 8 65 .4 80 . 2 71. 4 70. 3 69 .2 79. 6 91. 2 93. 0 (Amicar ) Indapamide (Lozol ) 64. 8 80 . 0 84 . 0 67 . 9 109 . 2 86 . 7 104 . 9 85 . 0 105. 8 65 . 5 76 . 8 92 . 7 101. 2 Simvastatin (Zocor ) 114 . 5 124 . 2 113 . 3 103 . 6 85 . 6 114 . 7 79 . 4 101 . 0 126 . 3 81 . 5 91. 8 99 . 9 69 . 0 Ramipril ( Altace ) 120 . 3 108 . 3 105 . 6 84 . 3 99 . 8 135 . 0 84 . 0 114 . 2 99 . 6 82 . 4 103 . 5 81 . 9 107. 3 Fenofibrate ( Tricor, 158 . 8 98 . 9 103. 7 98 . 3 84 . 1 122 . 0 83 . 1 103 . 2 101. 1 78 . 1 105 . 2 74 . 6 77 . 6 Trilipix ) Acadasine 99 . 1 88 . 7 103 . 1 88 . 4 75 . 4 100 . 9 81. 5 99 . 7 117 . 1 84 . 7 94 . 8 110 . 1 Acipimox 123. 9 79 . 4 99. 8 87. 6 87 .5 89 . 6 80 . 2 99 . 8 107. 8 75 . 8 94 . 5 102 . 2 Ticlopidine HCl 86 . 5 71 . 9 97 . 4 81. 9 77 . 2 61 . 6 72 . 7 111 . 5 84 . 9 96 . 8 699 . 90 . 5 101 . 8 Adiphenine HCI 87 . 6 133 . 9 95 . 5 96 . 4 109 . 118 . 7 95 . 7 82 . 0 86 . 8 102. 9 102 . 2 95 . 7 105 . 0 Rivastigmine tartrate 76 . 1 117 . 6 93 . 7 90 . 1 63 . 6 83 . 6 93 . 8 83 . 9 65 . 9 67 . 5 85 . 4 85 . 4 103 . 2 ( Exelon ) Detomidine HCI 84 . 8 133 . 0 102 . 3 88 . 8 68 . 5 90 . 6 91 . 0 74 . 2 81. 1 106 . 5 89 . 2 91 . 0 104 . 8 Gabexate mesylate 77. 9 114 . 9 92 . 0 83 . 1 75 . 0 69 . 8 81. 1 70 . 9 77. 3 89 . 6 94 . 2 89 . 1 117 . 6 Rasagiline mesylate 76 . 9 141 . 9 92 . 0 88 . 1 75 . 8 71 .8 87 . 7 74 . 2 91 . 3 88 . 3 103. 4 94 . 0 104 . 9 S - ( + ) - Rolipram 77 . 0 86 . 2 90 . 4 69 . 0 69 . 0 73 . 1 69. 9 81 . 1 71. 4 80 . 4 89. 3 94 . 1 107. 3 Tebipenem pivoxil ( L 60 . 4 92 . 2 73 . 8 67 . 4 63 . 7 76 . 4 77 . 4 82 . 3 73. 5 77 . 3 90 . 1 93 . 1 101 . 6 084 ) Aliskiren hemifumarate 91 . 2 97 . 2 94 . 2 107 . 8 81. 8 79 . 8 85 . 1 73 . 3 92 . 0 99 . 1 89 . 0 99 . 5 98 . 5 Milrinone (Primacor ) 101. 4 104 . 1 98 . 5 99 . 0 130 . 3 86 . 2 92 . 9 101 . 1 90 .9 98 . 5 92. 0 90 . 5 111 . 8 Novobiocin sodium 93. 4 115 . 9 92. 0 96 . 1 128 . 1 93 . 5 84. 4 85 . 3 95. 2 109 . 2 89 . 0 87 . 1 123 .4 (Albamycin ) Ozagrel 74 . 7 102 . 5 91. 2 77 . 7 98 . 5 80 . 6 93 . 9 69 . 44 77 . 7 101 . 8 101. 4 80 . 6 118 . 3 Pancuronium ( Pavulon ) 75 . 4 101 . 8 92 . 7 83 . 3 119 . 7 91. 7 95 . 3 68 . 3 100 . 0 110 . 3 107 . 5 79 . 8 108 . 8 Propafenone 95 . 8 109 . 2 86 . 0 108 . 8 79 . 8 92 . 5 84 . 7 61 . 1 94 . 1 119 . 7 104 . 4 105. 3 113 . 2 ( Rytmonorm ) US 2017 /0304388 A1 Oct. 26 , 2017

TABLE 3 -continued The inhibitory effect of cardiovascular drugs on various cancer cell lines Item Name A375 HCT116 (WT ) HepG2 HeLa AGS H1650 MKN - 45 TSGH A549 MCF7 PC3 LOVO HL -60 Xylazine HCI 63. 5 100 . 6 83 . 5 65 . 1 86 . 3 67. 2 88 . 7 61 . 5 71. 7 104 . 4 105 . 3 96 . 6 116 . 4 L - Adrenaline 101. 9 85 . 0 81 . 6 88 . 7 61 . 1 76 . 6 69 . 4 64 . 7 90 . 8 123 . 0 106 . 0 93 . 6 101. 8 ( Epinephrine ) Lonidamine 65 . 8 81. 2 114 . 2 61 . 6 69 . 9 65. 9 93 . 3 86 . 4 109 . 4 86 . 9 102 . 3 96 . 1 115 . 1 Bisacodyl 88 . 0 122 . 0 100 . 4 89 .2 107. 2 93. 6 132 . 3 104 . 3 66 . 7 65. 0 83 . 7 85 . 5 96 .0 Sodium Nitroprusside 78 . 9 125 . 6 85 . 2 107 . 4 96 . 4 109. 4 115 . 9 106 . 8 110 . 4 97 . 2 76 . 1 70. 9 81 . 7 Mefenamic acid 78 . 7 85 . 9 100 . 7 76 . 1 71 . 1 73. 9 114 . 8 118. 4 116 . 5 95 . 3 102 . 8 83 . 3 113 . 4 Ticagrelor 60 . 1 73 . 6 94 . 5 125 . 5 100 . 5 76 . 0 114 . 5 86 . 0 85 . 0 83 . 1 84 . 1 79 .6 93. 7 sulfacetamide sodium 64 . 9 76 . 7 98 . 7 75. 9 81. 4 79. 8 117. 8 120 . 3 70 . 0 110 .2 70 . 8 81 . 8 111 . 5 Levobetaxolol HCI 76 . 9 70 . 3 99 . 2 88 . 7 62 .5 69. 9 118. 6 98 . 2 75 . 9 85 . 0 771 .. 3 80 . 0 107 . 4 Dexlansoprazole 75 . 1 82 . 8 119 . 8 104. 7 89 . 8 69 .6 85 . 8 84 . 9 74 . 5 72 . 1 104 . 5 102 . 0 72 . 2 Chromocarb 63 .4 72 . 8 95 . 6 67. 6 81 . 8 78 . 8 100 . 3 97 . 2 61 . 1 100 . 4 88 . 3 72 . 5 110 . 1 Guanethidine Sulfate 81 . 1 83 . 7 85 . 5 75 . 9 863 . 88. 4 116 . 7 75 . 2 101 . 4 96 . 5 100 . 8 79 . 8 106 . 7 Isoetharine Mesylate 97 . 0 96 . 1 76 . 5 81. 6 96 . 6 91. 7 91. 0 88 . 3 76 . 7 102 . 7 71 . 6 100 . 2

[ 0037 ] Repeated experiments for growth inhibitory effects on cancer cell lines by various cardiovascular drugs in the present invention [ 0038 ] According to the above mentioned cardiovascular drugs for cancer growth inhibition in Table 3 , the inventors took the repeat experiments for the cardiovascular drugs to check the growth inhibitory effects of cancer cells by the cardiovascular drugs . The results were showed as Table . 4 . TABLE 4 The inhibitory effect of cardiovascular drugs on various cancer cell lines AGS MKN - 45 A549 H1650 TSGH - 8301 T24 Amlodipine besylate 12. 18342 86 .43411 110 .3104 110 . 2477 36 . 2492 93. 07934 (Norvase ) Nebivolol( Bystolic ) 26 . 60363 52. 82679 48 .95406 87. 37268 38 .02989 97 .6357 Pimobendan 60 . 81009 65 .23876 58 .25261 77 .77842 59 . 42484 74 . 23873 ( Vetmedin ) Cilnidipine 76 . 93947 105 .3923 67 . 8263 68 .97714 95 . 88997 107. 7523 Losartan potassium 74 . 09621 82 . 7996 96 .04947 77 . 1775 91. 97894 66 .27541 Prazosin HCl 86 . 83206 70 . 11645 72 . 20906 100 .6142 99 .83677 88 . 51161 Perindopril 87. 13689 73 . 83094 71. 92761 78 . 569 105 .3434 87 . 89513 Erbumine (Aceon ) Nisoldipine (Sular ) 64. 72004 98 .01894 48 . 91949 70 .00318 77 . 9189 67 . 81543 Amlodipine 16 .51631 88 . 19584 89 .21803 72 .01455 36 .20415 96 . 56012 (Norvase ) Benidipine 87 . 82976 92 .86011 70 . 30445 64 .52406 81. 48268 60 . 98854 hydrochloride 90 .22252 139 . 003987. 46658 39 .65028 115 . 122 79 . 46668 Ouabain 16 .61027 53 .00617 15 . 12608 38 . 72274 43 . 58029 17 . 57783 Disopyramide 95 . 87973 110 . 9738 99 . 4398990 . 5041 115 .4261 87 .62175 Phosphate Pitavastatin calcium 19 .17312 61. 30374 89 .44373 49. 9822 48 .91635 52 .63171 ( Livalo ) Simvastatin (Zocor ) 80 . 96248 92 .58344 109 .6818 79 .82892 105. 9187 89 .62686 Fluvastatin sodium 51. 95546 65 . 29484 98 . 76315 73. 07759 78 . 17048 71. 79614 ( Lescol) Atorvastatin calcium 31 . 48172 84 . 18125 90 . 1462 69 . 54683 70 . 5892778 . 47023 ( Lipitor ) HepG2 Hep3B HCT116 LoV Hela C -33A Amlodipine besylate 95 .00681 123. 4192 78 .25503 85 .56338 101. 287 33 . 71715 (Norvase ) Nebivolol( Bystolic ) 42. 12209 44 .81568 81 .90311 85 . 28787 52 . 00985 76 .97273 Pimobendan 87. 23618 94 .82416 53 .63161 66 .73545 34 . 00865 62. 77014 ( Vetmedin ) Cilnidipine 77 . 12693 92. 70906 88 .59966 53. 71666 64 . 33688 92 . 99393 Losartan potassium 93 . 9165 102 .6817 105 . 8013 106 . 1105 83. 41553 108 . 1531 Prazosin HCI 87 . 24 115 .7343 96 .42385 95 .70664 90 . 90437 97 . 23898 Perindopril 99. 43144 99 . 52974 64 . 99606 83 . 48715 66 .66128 90 . 91624 Erbumine ( Aceon ) US 2017 /0304388 A1 Oct. 26 , 2017

TABLE 4 -continued The inhibitory effect of cardiovascular drugs on various cancer cell lines Nisoldipine ( Sular ) 95 . 50526 130 .2372 77 . 38842 76 .88917 76 .89186 65 .96391 Amlodipine 71 .75803 99. 21563 91 . 96059 90 .33212 86 .95599 38 . 17616 (Norvase ) Benidipine 83. 57118 98 .76207 90 .62094 69 . 00425 92 .92617 105 . 186 hydrochloride Azelnidipine 100 .8108 98 .58296 111 .283 59. 86935 87 .03299 123 . 2929 Ouabain 38 .05699 33 . 35996 15 . 8664 39 .68181 23 . 12941 35 . 48352 Disopyramide 108 .9905 113. 0039 93. 97825 104 .5373 102. 7953 98 . 46569 Phosphate Pitavastatin calcium 98 .05696 96 .33898 35 .06809 65. 14687 36 .90614 74 .75168 ( Livalo ) Simvastatin (Zocor ) 124 . 3915 113 .5223 83 . 19968 89 . 30886 100. 3977 112 .4884 Fluvastatin sodium 104 .3733 108 .8002 54 .97113 99 .98781 54 .32329 89. 50117 ( Lescol) Atorvastatin calcium 95 .92241 91 .85783 82 .55431 103 .0307 78 .64343 96 .94654 (Lipitor ) MDA - NIH PC - 3 MCF -7 MB231 OVCAR - 3 TOV -216 |ASPC - 1 Amlodipine besylate 73. 55958 80 . 48625 82 .71348 91 .55643 93. 54755 87. 83891 (Norvase ) Nebivolol ( Bystolic ) 36 .95159 27 .04214 66 .43548 86 .76822 86 .16763 88 .66097 Pimobendan 69 .47215 53. 94911 75 .04087 74 .72196 70 . 73536 69. 30304 ( Vetmedin ) Cilnidipine 61. 39718 64 .63051 86 . 26857 75 . 85887 62 . 8999 57 . 59939 Losartan potassium 119 . 8879 87 .64286 101. 4346 98 . 7328 78 .5729 86 . 43686 Prazosin HCI 100 . 7353 87 .60617 85 .08244 88 .88644 91. 8658 80 . 37522 Perindopril 81 . 06817 75 .64154 63 . 78244 79 . 59739 71. 22602 64 . 22167 Erbumine ( Aceon ) Nisoldipine (Sular ) 98 . 90966 86 .64786 74 .06174 68 . 14248 44 .35767 78. 75132 Amlodipine 85 .88287 63. 42196 87 .55328 90 .31382 61. 32005 89. 03664 (Norvase ) Benidipine 88 . 48559 77. 28047 77 . 34072 85 .24836 47. 45143 63 .35622 hydrochloride Azelnidipine 120 .9111 60 . 82186 86 .91866 102 .4284 27 . 15468 53 . 57238 Ouabain 25 .76337 29 . 14322 44 .49393 42. 33431 15 . 89529 20 .08356 Disopyramide 103 . 4303 107. 038 98 . 77022 102. 8007 94 . 30529 77. 1867 Phosphate Pitavastatin calcium 27. 53778 83. 56777 39 .0358 61 .40586 21. 78861 51 . 36252 (Livalo ) Simvastatin (Zocor ) 92 .77994 88 .80292 71 .08201 98 .38307 63. 61464 78 . 20757 Fluvastatin sodium 32 . 11203 82 .4571 43. 03235 84 .73175 50 . 48937 83. 55133 ( Lescol) Atorvastatin calcium 56 . 4832 79. 08152 47. 83606 98 . 29788 34 .04009 81. 09956 (Lipitor ) BxPC - 3 SAS U2OS A375 BCC 786 - 0 Amlodipine besylate 99. 10538 94 .7983 71. 05736 136 .6675 102. 9778 73. 16328 (Norvase ) Nebivolol (Bystolic ) 74 .42236 75 .56914 66 .6423 44. 93539 55 .82216 38 .30332 Pimobendan 51. 86991 51. 11398 56 .58073 44 .3967 49 . 56082 39. 63967 ( Vetmedin ) Cilnidipine 68 .6671 38. 91442 43 .14859 47. 06953 60 . 17311 86 . 69656 Losartan potassium 77 . 73778 95 .71052 105 . 448396 .64672 90 . 16032 96 . 33382 Prazosin HCl 54 .00243 114 .3263 97. 95575 77. 91429 73 .45319 79 . 5367 Perindopril 49. 97129 52. 47616 73. 98258 83 .20685 58 .7078986 . 19895 Erbumine ( Aceon ) Nisoldipine ( Sular ) 75 . 55234 48 .80258 69 . 11154 51. 46547 58 .78716 49 .50878 Amlodipine 86 .01719 99. 20403 78 .90455 81. 57538 74 . 9299 81 . 41545 ( Norvase ) Benidipine 73 . 78347 64 . 48332 54 . 15218 76 .0146774 .60455 78 . 8709 hydrochloride Azelnidipine 64 . 6017 76 .82412 69 .39511 101. 1726 100 .2223 86 .81704 Ouabain 27 .01516 20 .23483 22 . 80353 18 .38812 25 .61877 14 .51443 Disopyramide 69. 94309 96. 93263 98. 72214 113. 872 109. 7018 102. 4512 Phosphate Pitavastatin calcium 59. 77881 38 .0374 43. 44485 22 .09494 26 .77364 16 . 46038 ( Livalo ) US 2017 /0304388 A1 Oct. 26 , 2017 7

TABLE 4 -continued The inhibitory effect of cardiovascular drugs on various cancer cell lines Simvastatin (Zocor ) 81. 82199 83. 91121 65 . 60642 78 .63685 57. 35253 87 . 7969 Fluvastatin sodium 79 . 10141 81. 50136 91. 20342 21. 78962 27 .03446 23. 64486 ( Lescol ) Atorvastatin calcium 81. 02839 76 .29143 86 . 25076 23. 01045 41. 49497 32. 53672 ( Lipitor )

1. A method for treating a cancer comprising : adminis dehydrate , Solifenacin succinate , Methyclothiazide, Benz tering to a subject in need thereof a pharmaceutical compo , Meticrane , Bendroflumethiazide , and Potassium sition comprising a therapeutically effective amount of a Canrenoate . cardiovascular drug or a pharmaceutical acceptable salt 7 . The method of claim 2 , wherein the antiarrhythmic thereof. agent is selected from the group consisting of Adenosine (Adenocard ), Dofetilide ( Tikosyn ), Amiodarone HCI, 2 . Themethod of claim 1, wherein the cardiovascular drug Ibutilide fumarate , Propafenone (Rytmonorm ), and Disopy is selected from the group consisting of peripheral vasodi ramide Phosphate . lator reaming enhancer, angiotensin converting agent inhibi 8 . The method of claim 2 , wherein the antiarralciton drug tor, hypotension and shock therapeutic agent, diuretic , anti is selected from the group consisting of Dexrazoxane arrhythmic agent, antiarralciton drug , antihypertensive Hydrochloride , Ranolazine dihydrochloride , Nisoldipine agent, anticoagulant thrombolytic agent, cardiac tonic , and (Sular ) , Ranolazine (Ranexa ), Acadesine , Nifedipine (Ada intravenous (hemorrhoids ) therapeutic agent. lat) , Amlodipine besylate (Norvasc ), Diltiazem HC1 ( Ti azac ) , Ticagrelor, and Oxprenolol HC1. 3 . The method of claim 2 , wherein the peripheral vaso 9 . The method of claim 2 , wherein the antihypertensive dilator reaming enhancer is selected from the group con agent is selected from the group consisting of Bisoprolol, sisting of Cilnidipine , Minoxidil , Prazosin HCl, Sildenafil Doxazosin mesylate , Alfuzosin hydrochloride (Uroxatral ) , citrate , Tadalafil (Cialis ) , Nicorandil ( Ikorel) , Lacidipine Nebivolol (Bystolic ) , Reserpine , Methyldopa (Aldomet ) , ( Lacipil , Motens ), Benidipine hydrochloride , Cilazapril Eplerenon , Nimodipine (Nimotop ) , Betaxolol hydrochloride monohydrate ( Inhibace ) , Fosinopril sodium (Monopril ) , (Betoptic ) , Carvedilol, Metoprolol tartrate, Felodipine Almotriptan malate ( Axert) , Milrinone (Primacor ), Avanafil , (Plendil ) , Amlodipine (Norvasc ) , Phentolamine mesilate , Lomerizine HC1, Histamine Phosphate , Chromocarb , and Imidapril ( Tanatril ) HC1, Aliskiren hemifumarate , Sodium Pinacidil . Nitroprusside , Propranolol HC1, Levobetaxolol HC1, Esmolol HC1, ( R ) - ( + ) - Atenolol, Guanethidine Sulfate , and 4 . The method of claim 2 , wherein the angiotensin con Lofexidine HCI. verting agent inhibitor is selected from the group consisting 10 . The method of claim 2 , wherein the anticoagulant of Benazepril hydrochloride , Losartan potassium , Perindo thrombolytic agent is selected from the group consisting of pril Erbumine ( Aceon ) , Irbesartan ( Avapro ) , Candesartan Prasugrel (Eflient ) , Cilostazol, Nafamostat mesylate , Clopi ( Atacand ) , Olmesartan medoxomil ( Benicar ) , Enalaprilat dogrel (Plavix ) , Apixaban , Aminocaproic acid (Amicar ), dehydrate , Telmisartan (Micardis ) , Ramipril ( Altace ) , Val Dipyridamole (Persantine ), Phenindione (Rectadione ) , sartan (Diovan ), Enalapril maleate (Vasotec ) , Candesartan Ticlopidine HCI, Ozagrel HC1, Argatroban , Bexarotene , cilexetil (Atacand ), Conivaptan HCl (Vaprisol ) , Azilsartan Gabexate mesylate , and Ozagrel and Anisindione. Medoxomil ( TAK -491 ) , and Eprosartan Mesylate . 11 . The method of claim 2 , wherein the cardiac tonic is selected from the group consisting of Pimobendan ( Vetme 5 . The method of claim 2 , wherein the hypotension and din ), Ampiroxicam , Digoxigenin , and Pindolol. shock therapeutic agent is selected from the group consisting 12 . The method of claim 2 , wherein the intravenous of L -Adrenaline (Epinephrine ), DL - Adrenaline , and (hemorrhoids ) therapeutic agent is selected from the group Methoxamine HCl. consisting of Edaravone (MCI - 186 ) , Daidzein , Ginkgolide 6 . The method of claim 2 , wherein the diuretic is selected A , and Bisacodyl. from the group consisting of Bumetanide , Furosemide 13 . The method of claim 1 , wherein the cancer is selected (Lasix ) , Metolazone( Zaroxolyn ), Silodosin (Rapaflo ), Chlo from the group consisting of lung cancer, intestinal cancer, rothiazide, Trichlormethiazide ( Achletin ) , Torsemide (De colorectal cancer, prostate cancer, liver cancer, bladder can madex ) , Hydrochlorothiazide , Indapamide ( Lozol) , Dichlo cer, cervical cancer, breast cancer, and blood cancer. rphenamide (Diclofenamide ) , Amiloride hydrochloride * * * * *